Skip to main content

Table 1 Baseline characteristics

From: Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease

 

NC (n = 37)

Patients with AD (n = 24)

p Value

Age, years

65.1 ± 7.3

67.6 ± 7.6

0.2005

Male sex

16 (43.2%)

13 (56.5%)

0.6965

Education, years

12.2 ± 3.9

13.1 ± 4.0

0.3659

MMSE score, median

29

19

<0.0001

ApoE ε4 carriera

5 (17.2%)

11 (45.8%)

0.018

CSF Aβ42 b, pg/ml

465 ± 117

259 ± 72

< 0.0001

CSF t-Tau/Aβ42 ratiob

0.1157

0.4184

< 0.0001

PIB SUVRb

1.11

1.61

< 0.0001

  1. Abbreviations: AD Alzheimer’s disease, NC Cognitively normal control subjects, 42 Amyloid-β 1–42 peptide, CSF Cerebrospinal fluid, MMSE Mini Mental State Examination, ApoE Apolipoprotein E, PIB SUVR 11C-Pittsburgh compound B standardized uptake value ratio, pTau Phosphorylated tau protein, tTau Total tau protein
  2. aTwenty-four patients with AD and 29 NC were evaluated for the presence of the ApoE ε4 allele
  3. bTwenty-three patients with AD and 28 NC were assessed by CSF and PIB positron emission tomography studies